Veru Inc. (VERU) Reaches $2.07 After 3.00% Up Move; Albemarle (ALB) Shorts Down By 14.45%

June 12, 2018 - By reb123z

Albemarle Corporation (NYSE:ALB) Logo

The stock of Veru Inc. (NASDAQ:VERU) is a huge mover today! The stock increased 5.08% or $0.1 during the last trading session, reaching $2.07. About 75,858 shares traded. Veru Inc. (NASDAQ:VERU) has risen 65.00% since June 12, 2017 and is uptrending. It has outperformed by 52.43% the S&P500. Some Historical VERU News: ; 09/05/2018 – Veru 2Q Loss/Shr 7c; 06/03/2018 – VERU INC – CO RECEIVED NET PROCEEDS OF ABOUT $9.9 MLN FROM INITIAL $10 MLN ADVANCE UNDER CREDIT AGREEMENT; 06/03/2018 – VERU INC – IN CONNECTION WITH CREDIT AGREEMENT, VERU AND SWK FUNDING ALSO ENTERED INTO A RESIDUAL ROYALTY AGREEMENT, DATED AS OF MARCH 5, 2018; 17/05/2018 – Veru Announces Publication of Data from Three Cancer Studies as Part of the Upcoming American Society of Clinical Oncology Annual Meeting; 16/03/2018 – VERU REPORTS POTENT ACTIVITY AGAINST PROSTATE CANCER MODELS; 17/05/2018 – Veru Announces Publication of Data on Oral VERU-111 in Prostate Cancer in Connection with the 2018 American Society of Clinica; 03/05/2018 – Veru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 American Urological Association Meeting; 17/05/2018 – Veru: Data Demonstrates Greater Efficacy of Oral VERU-111 in Highly Resistant Prostate Cancer; 09/05/2018 – Veru 2Q Loss $3.83M; 17/05/2018 – Veru Announces Publication of Data on Oral VERU-111 in Prostate Cancer in Connection with the 2018 American Society of Clinical Oncology Annual MeetingThe move comes after 5 months positive chart setup for the $110.77 million company. It was reported on Jun, 12 by Barchart.com. We have $2.13 PT which if reached, will make NASDAQ:VERU worth $3.32 million more.




Albemarle Corporation (NYSE:ALB) had a decrease of 14.45% in short interest. ALB’s SI was 10.48 million shares in June as released by FINRA. Its down 14.45% from 12.25M shares previously. With 2.01M avg volume, 5 days are for Albemarle Corporation (NYSE:ALB)’s short sellers to cover ALB’s short positions. The SI to Albemarle Corporation’s float is 9.52%. The stock increased 0.89% or $0.85 during the last trading session, reaching $96.22. About 1.07M shares traded. Albemarle Corporation (NYSE:ALB) has declined 15.78% since June 12, 2017 and is downtrending. It has underperformed by 28.35% the S&P500. Some Historical ALB News: ; 09/03/2018 – Albemarle Corp Receives Increase in Lithium Quota for Chile Ops; 17/04/2018 – Soaring Demand for Lithium Fuels Exploration and Production Race; 14/05/2018 – Carmignac Gestion Buys New 1.1% Position in Albemarle; 14/05/2018 – ALBEMARLE CORP – PURCHASES WILL BE FUNDED THROUGH AVAILABLE CASH ON HAND; 09/05/2018 – Albemarle 1Q Net $131.8M; 03/04/2018 – China miner Tianqi meets with Chilean anti-trust prosecutor on SQM; 10/05/2018 – ALBEMARLE: 2018 LITHIUM MARGINS TO TOP 40%; 22/03/2018 – New Chilean Government Spells Lithium Mining Boom: The White Gold Rush; 19/04/2018 – ALBEMARLE DECLARES FORCE MAJEURE DUE TO SHORTAGE OF KEY RAW; 10/05/2018 – ALBEMARLE CALL CONCLUDES

Among 23 analysts covering Albemarle Corporation (NYSE:ALB), 16 have Buy rating, 1 Sell and 6 Hold. Therefore 70% are positive. Albemarle Corporation had 78 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Thursday, February 23 by RBC Capital Markets. The firm earned “Neutral” rating on Monday, November 13 by Citigroup. The firm earned “Buy” rating on Thursday, November 9 by Oppenheimer. The firm earned “Buy” rating on Friday, June 16 by Jefferies. The rating was maintained by UBS with “Neutral” on Thursday, November 9. The company was maintained on Monday, February 5 by Seaport Global. The firm earned “Buy” rating on Monday, October 23 by Jefferies. The firm has “Buy” rating given on Wednesday, April 19 by RBC Capital Markets. RBC Capital Markets maintained Albemarle Corporation (NYSE:ALB) on Tuesday, October 17 with “Buy” rating. Deutsche Bank maintained Albemarle Corporation (NYSE:ALB) on Thursday, August 20 with “Buy” rating.

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. The company has market cap of $10.66 billion. The firm offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties and reagents for applications in lithium batteries, high performance greases, thermoplastic elastomers for car tires, rubber soles and plastic bottles, catalysts for chemical reactions, organic synthesis processes, life science, pharmaceutical, and other markets; cesium products for the chemical and pharmaceutical industries; and zirconium, barium, and titanium products for pyrotechnical applications. It has a 79.19 P/E ratio. It also makes cesium products for the chemical and pharmaceutical industries; and zirconium, barium, and titanium products for various pyrotechnical applications, including airbag igniters; and performance catalyst solutions, such as polymer catalysts, curatives, organometallics, and electronic materials for polyolefin polymers, packaging, non-packaging, films, injection molding, alpha-olefins, electronic materials, solar cells, polyurethanes, epoxies, and other engineered resins markets.

More important recent Albemarle Corporation (NYSE:ALB) news were published by: Fool.com which released: “SQM vs. Albemarle vs. FMC Corp.: Which Had the Best Lithium Results in Q1?” on May 30, 2018, also Investorplace.com published article titled: “Despite Growing Pains, Solar Stocks Have Inevitability Behind Them”, Seekingalpha.com published: “Honeywell, Dover among companies exiting Iran presence before sanctions” on June 05, 2018. More interesting news about Albemarle Corporation (NYSE:ALB) was released by: Seekingalpha.com and their article: “Wall Street Breakfast: ECB Steps Toward Exiting QE” with publication date: June 06, 2018.

Investors sentiment decreased to 0.99 in 2018 Q1. Its down 0.02, from 1.01 in 2017Q4. It dived, as 82 investors sold Albemarle Corporation shares while 156 reduced holdings. 72 funds opened positions while 163 raised stakes. 93.28 million shares or 0.45% more from 92.86 million shares in 2017Q4 were reported. Ferguson Wellman reported 0.01% of its portfolio in Albemarle Corporation (NYSE:ALB). Louisiana State Employees Retirement has 0.03% invested in Albemarle Corporation (NYSE:ALB) for 6,800 shares. Winch Advisory Limited Liability Company reported 491 shares or 0.03% of all its holdings. Oppenheimer Co, New York-based fund reported 22,073 shares. Td Asset Mngmt holds 0% in Albemarle Corporation (NYSE:ALB) or 34,379 shares. Moreover, Point72 Asia (Hong Kong) has 0.08% invested in Albemarle Corporation (NYSE:ALB) for 1,669 shares. Commonwealth Bank Of Aus invested in 0% or 132 shares. Regions Fincl owns 652 shares for 0% of their portfolio. Cim Investment Mangement holds 9,145 shares. The New York-based Guardian Life Commerce Of America has invested 0% in Albemarle Corporation (NYSE:ALB). Smithfield holds 0.01% of its portfolio in Albemarle Corporation (NYSE:ALB) for 928 shares. Capital Mgmt Corporation Va stated it has 2.19% of its portfolio in Albemarle Corporation (NYSE:ALB). Amalgamated Savings Bank owns 0.03% invested in Albemarle Corporation (NYSE:ALB) for 14,166 shares. Cypress Asset Management Tx stated it has 0.16% in Albemarle Corporation (NYSE:ALB). Mason Street Limited Liability Co has 15,412 shares.

More recent Veru Inc. (NASDAQ:VERU) news were published by: Nasdaq.com which released: “Veru to Start Phase 2 Trial to Evaluate Cis-Clomiphene Citrate to Treat Hot Flashes Caused by Advanced Prostate …” on June 12, 2018. Also Nasdaq.com published the news titled: “Veru to Present at Jefferies 2018 Global Healthcare Conference on Wednesday, June 6th” on May 30, 2018. Globenewswire.com‘s news article titled: “Veru Announces Publication of Data on Oral VERU-111 in Prostate Cancer in Connection with the 2018 American …” with publication date: May 17, 2018 was also an interesting one.

Veru Inc. operates as a urology and oncology biopharmaceutical company. The company has market cap of $110.77 million. The firm operates through two divisions, Commercial; and Research and Development. It currently has negative earnings. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Analysts await Veru Inc. (NASDAQ:VERU) to report earnings on August, 14. They expect $-0.05 EPS, down 66.67% or $0.02 from last year’s $-0.03 per share. After $-0.07 actual EPS reported by Veru Inc. for the previous quarter, Wall Street now forecasts -28.57% EPS growth.

Albemarle Corporation (NYSE:ALB) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.